OpenNashEarnings

IQVIA (IQV) · Life Sciences

IQVIA Q2 2026 earnings: summary, key numbers & outlook

Results filed 28 Jul 2026 · Quarter ended 30 Jun 2026

Slides (15 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

IQVIA reported record R&D Solutions net new bookings of over $3.1 billion and rising adoption of its AI solutions, and said forward indicators point to sustained momentum into 2027.

IQVIA's R&D Solutions unit, which runs clinical trials for drug developers, signed record net new bookings of over $3.1 billion, lifting contracted backlog to $34.2 billion. In Commercial Solutions, patient solutions and commercial engagement services grew at double-digit rates, and analytics and consulting grew at a high-single-digit organic rate. Management also pointed to increased adoption of its AI solutions. Since January 1, 2026, results have been reported under a simplified two-segment structure.

Management says forward-looking indicators across both segments point to sustained momentum for the rest of 2026 and into 2027, and it raised its full-year outlook. About $9.2 billion of backlog is expected to convert to revenue over the next twelve months. The main tension is execution: the plan relies on turning record bookings into revenue and on the new organizational model delivering its expected benefits, with acquisitions contributing more to growth than previously assumed.

No call transcript for this quarter, so this summary also draws on: Quartr ↗, BriefGlance ↗.

Slides & documents

Open the slide deck (PDF, 15 pages) ↗

IQVIA Q2 2026 slide deck, page 1IQVIA Q2 2026 slide deck, page 2IQVIA Q2 2026 slide deck, page 3IQVIA Q2 2026 slide deck, page 4IQVIA Q2 2026 slide deck, page 5IQVIA Q2 2026 slide deck, page 6

Showing the first 6 of 15 pages.

From IQVIA investor relations

SEC filing

Key numbers

Revenue · GAAP
$4,368 million

up 8.7% year-over-year

Net income · GAAP
$256 million

Diluted EPS · GAAP
$1.53

Adjusted diluted EPS · non-GAAP
$3.15

up 12.1% year-over-year

Adjusted EBITDA · non-GAAP
$994 million

up 9.2% year-over-year

Operating cash flow · GAAP
$558 million

up 26.0% year-over-year

Free cash flow · non-GAAP
$360 million

up 23.3% year-over-year

Segment or metricValueChange
Commercial Solutions revenue$1,793 millionup 8.6% year-over-year
R&D Solutions revenue$2,575 millionup 8.8% year-over-year
R&DS net new bookings$3.15 billionup 19% year-over-year
R&DS contracted backlog$34.2 billion
Last-twelve-months net new bookings$11.3 billionup 13% year-over-year
Where each number comes from
  • Revenue: “Revenue for the second quarter of $4,368 million increased 8.7% on a reported basis and 8.5% at constant currency, compared to the second quarter of 2025.”
  • Net income: “Second-quarter GAAP Net Income was $256 million and GAAP Diluted Earnings per Share was $1.53.”
  • Diluted EPS: “Second-quarter GAAP Net Income was $256 million and GAAP Diluted Earnings per Share was $1.53.”
  • Adjusted diluted EPS: “Adjusted Net Income was $527 million and Adjusted Diluted Earnings per Share was $3.15, up 12.1% year-over-year.”
  • Adjusted EBITDA: “Adjusted EBITDA was $994 million, up 9.2% year-over-year.”
  • Operating cash flow: “For the second quarter, Operating Cash Flow was $558 million, up 26.0% year-over-year, and Free Cash Flow was $360 million, up 23.3% year-over-year.”
  • Free cash flow: “For the second quarter, Operating Cash Flow was $558 million, up 26.0% year-over-year, and Free Cash Flow was $360 million, up 23.3% year-over-year.”
  • Commercial Solutions revenue: “Commercial Solutions revenue of $1,793 million increased 8.6% on a reported basis and 8.4% at constant currency.”
  • R&D Solutions revenue: “Research & Development Solutions revenue of $2,575 million grew 8.8% on a reported basis and 8.6% at constant currency.”
  • R&DS net new bookings: “Second quarter net new bookings were $3.15 billion, an increase of 19% year-over-year, resulting in a book-to-bill ratio of 1.22x.”
  • R&DS contracted backlog: “As of June 30, 2026, R&DS contracted backlog was $34.2 billion.”
  • Last-twelve-months net new bookings: “The last-twelve months net new bookings were $11.3 billion, up 13% year-over-year.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$4.4B+8.7%+5.2%
Operating income$506.0M+0.0%−1.6%
Net income$256.0M−3.8%−6.6%
Diluted EPS$1.53−0.6%−5.0%
Free cash flow$360.0M+23.3%−26.7%
Operating margin11.6%−1.0 pts−0.8 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Q3 revenuethird quarter of 2026$4,315 – $4,390
Q3 Adjusted EBITDAthird quarter of 2026$1,000 – $1,020
Q3 Adjusted diluted EPSthird quarter of 2026$3.19 – $3.29
Full-year revenuefull-year 2026$17,275 million and $17,475 million
Full-year Adjusted EBITDAfull-year 2026$4,000 million and $4,050 million
Full-year Adjusted diluted EPSfull-year 2026$12.80 and $13.00

Key takeaways

  1. R&D Solutions bookings hit a record level

    Net new bookings were $3.15 billion, a 1.22x book-to-bill ratio, and the release calls them record-level. Strong bookings give IQVIA's clinical research business demand visibility ahead.

  2. Backlog of $34.2 billion supports future R&D revenue

    About $9.2 billion of contracted backlog is expected to convert to revenue in the next twelve months, representing growth of 7.5% year-over-year. This shows how much near-term work is already contracted.

  3. AI solutions adoption is helping Commercial Solutions accelerate

    Management cited increased adoption of its AI solutions as a contributor to stronger organic growth in Commercial Solutions. It positions IQVIA's AI offerings as a driver of demand, not only a branding theme.

  4. Patient solutions and engagement services grow double digits

    Within Commercial Solutions, patient solutions and commercial engagement services both grew at double-digit rates, while analytics and consulting grew at a high-single-digit organic rate. Growth is broad across the segment's service lines.

  5. Acquisitions now contribute more to growth

    The updated guidance assumes approximately 200 basis points of contribution from acquisitions versus 150 basis points previously. Management is leaning more on M&A alongside higher organic growth, and has raised its outlook for the year.

Charts

Revenue$4.4B+8.7% y/yQ2 2026
Q4 2024: $4.0B (worked out from the annual figure)Q4 ’24$4.0BQ1 2025: $3.8BQ1 ’25$3.8BQ2 2025: $4.0BQ2 ’25$4.0BQ3 2025: $4.1BQ3 ’25$4.1BQ4 2025: $4.4B (worked out from the annual figure)Q4 ’25$4.4BQ1 2026: $4.2BQ1 ’26$4.2BQ2 2026: $4.4BQ2 ’26$4.4BQ3 2026: $4.4BQ3 ’26$4.4B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$4.0B *
Q1 2025$3.8B
Q2 2025$4.0B
Q3 2025$4.1B
Q4 2025$4.4B *
Q1 2026$4.2B
Q2 2026$4.4B
Q3 2026$4.4B
Diluted EPS (GAAP)$1.53−0.6% y/yQ2 2026
Q1 2025: $1.40Q1 ’25$1.40Q2 2025: $1.54Q2 ’25$1.54Q3 2025: $1.93Q3 ’25$1.93Q1 2026: $1.61Q1 ’26$1.61Q2 2026: $1.53Q2 ’26$1.53Q3 2026: $2.10Q3 ’26$2.10
Data
Q1 2025$1.40
Q2 2025$1.54
Q3 2025$1.93
Q1 2026$1.61
Q2 2026$1.53
Q3 2026$2.10

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin11.6%−1.0 pts y/yQ2 2026
Q4 2024: 15.8%Q4 ’2415.8%Q1 2025: 13.0%Q1 ’2513.0%Q2 2025: 12.6%Q2 ’2512.6%Q3 2025: 13.5%Q3 ’2513.5%Q4 2025: 14.4%Q4 ’2514.4%Q1 2026: 12.4%Q1 ’2612.4%Q2 2026: 11.6%Q2 ’2611.6%Q3 2026: 12.9%Q3 ’2612.9%
Data
Q4 202415.8%
Q1 202513.0%
Q2 202512.6%
Q3 202513.5%
Q4 202514.4%
Q1 202612.4%
Q2 202611.6%
Q3 202612.9%
Free cash flow$360.0M+23.3% y/yQ2 2026
Q4 2024: $721.0MQ4 ’24$721.0MQ1 2025: $426.0MQ1 ’25$426.0MQ2 2025: $292.0MQ2 ’25$292.0MQ3 2025: $772.0MQ3 ’25$772.0MQ4 2025: $561.0MQ4 ’25$561.0MQ1 2026: $491.0MQ1 ’26$491.0MQ2 2026: $360.0MQ2 ’26$360.0MQ3 2026: $667.0MQ3 ’26$667.0M
Data
Q4 2024$721.0M
Q1 2025$426.0M
Q2 2025$292.0M
Q3 2025$772.0M
Q4 2025$561.0M
Q1 2026$491.0M
Q2 2026$360.0M
Q3 2026$667.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What was the biggest business development at IQVIA this quarter?

R&D Solutions posted record-level net new bookings of over $3.1 billion, a 1.22x book-to-bill ratio. Management said favorable forward-looking indicators across both segments point to sustained momentum for the rest of the year and into 2027.

How is AI affecting IQVIA's business?

Management said increased adoption of its AI solutions contributed to a strong acceleration of organic revenue growth in Commercial Solutions. The sources give no further detail on specific AI products or usage.

Which Commercial Solutions lines are growing fastest?

Patient solutions and commercial engagement services grew at double-digit rates. Analytics and consulting grew at a high-single-digit organic rate.

How much future clinical research revenue is already contracted?

R&DS contracted backlog was $34.2 billion as of June 30, 2026. IQVIA expects approximately $9.2 billion of it to convert to revenue in the next twelve months, representing growth of 7.5% year-over-year.

Did IQVIA change its outlook or how it is organized?

Yes. It raised its full-year 2026 guidance, citing stronger organic growth and a larger acquisition contribution, partly offset by a less favorable foreign exchange impact. Since January 1, 2026, it has reported two segments, Commercial Solutions and R&D Solutions, under a simplified organizational model.